Interchangeable Insulin Biosimilars: A Game Changer in Diabetes Management

The panel of experts in the management of diabetes review the role of insulin therapy and the place for biosimilars. They will review the approval process for biosimilars including the approval of the first interchangeable insulin biosimilar.

Basal Insulin Therapies for Diabetes Management

December 1st 2021

Diana Isaacs, PharmD, BCPS, BCACP, BC-ADM, CDCES, and Thomas C. Blevins, MD, ECNU, FACE, FNLA, review FDA-approved basal insulins for the management of diabetes.

Role of Interchangeable Biosimilars in the Management of Diabetes

December 1st 2021

Thomas C. Blevins, MD, ECNU, FACE, FNLA, provides an overview of biosimilars and discusses interchangeability status among biosimilars such as for insulin glargine-yfgn for the management of diabetes.

Results of INSTRIDE Studies for Diabetes Management

December 1st 2021

Experts in diabetes management discuss data from key clinical trials—INSTRIDE 1, INSTRIDE 2, and INSTRIDE 3—and evaluate the use of insulin glargine-yfgn as an interchangeable product with biologics.

Impact of Interchangeable Insulin Biosimilars on Cost of Biologics

December 1st 2021

Thomas C. Blevins, MD, ECNU, FACE, FNLA, and Diana Isaacs, PharmD, BCPS, BCACP, BC-ADM, CDCES, discuss the impact of interchangeable insulin biosimilars on biologic products in the marketplace for diabetes management.

Challenges to Biosimilar Adoption of Insulin Glargine-yfgn

December 1st 2021

Thomas C. Blevins, MD, ECNU, FACE, FNLA, leads the discussion on potential challenges to the adoption of biosimilars in clinical practice, such as for insulin glargine-yfgn in diabetes management, and discusses the importance of patient and provider education.

Future Directions for the Use of Biosimilars in Diabetes

December 1st 2021

Drs Thomas C. Blevins and Diana Isaacs share insight on unmet needs and the future treatment landscape of biosimilars in the treatment of patients with diabetes.